| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3b topline data readout example | Phase 3b | — | Subscribe to access the data. | Cell Therapies | Nervous System | ||
Phase 3b topline data readout example | Phase 3b | — | Subscribe to access the data. | Cell Therapies | Nervous System | ||
Phase 3b topline data readout example | Phase 3b | — | Subscribe to access the data. | Cell Therapies | Nervous System |
Recent Updates
Recently added Catalysts
Brainstorm Cell Therapeutics Inc.$0.68
-0.02 (-3.53%)
D 22Pipeline Score Richly Valued Biotech · Clinical
Market Cap
11.51 M
EPS
-1.98
P/E Ratio
-
Value Trade
1.27 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
762.00 K
Operating CF
-1.32 M
Total Assets
755.00 K
Total Liabilities
11.76 M
Equity
-11.01 M
-6.77 %
Week
-6.4 %
1 Month
44.44 %
3 Month
-40.91 %
6 Month
-99.44 %
5 Year
-75.52 %
All Time
Cash Data
Cash Position
206.00 K
Monthly Burn
440.00 K
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
1.82 K
52 Week Range
0.72 - 6
% held by Insiders
22.32 %
% held by Institutions
10.4 %
Enterprise Value
11.64 M
Total Shares
9.84 M
Short %
6.06 %
Float Shares
7.64 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-10-23 | Debamestrocel | Phase 3b data readout | Phase 3b | — | – | – | – |
2024-10-23 | Debamestrocel | Phase 3b data readout | Phase 3b | — | – | – | – |
2024-10-23 | Debamestrocel | Phase 3b data readout | Phase 3b | — | – | – | – |
Drug Pipeline Intelligence
D22
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 22%
Micro Cap (rank 721 of 923)
Percentile RankBrainstorm Cell Therapeutics Inc. faces pipeline headwinds (22/100), with $509M risk-adjusted pipeline value, led by NurOwn in Multiple Sclerosis, Chronic Progressive (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NurOwn Monoclonal antibody | Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | NCT03280056 | 69% | $455M | COMPLETED | 196 | - | - | Sep 29, 2020 | - | Feb 29, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NurOwn Fast TrackOrphan | ALS | Phase 3b | 2025-07-08 | participants survived more than five years from ALS symptom onset; the median survival in the group was 6.8 years Read More | FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness Read More | |
NurOwn Fast TrackOrphan | ALS | Phase 3b | 2025-07-08 | participants survived more than five years from ALS symptom onset; the median survival in the group was 6.8 years Read More | FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness Read More | |
NurOwn Fast TrackOrphan | ALS | Phase 3b | 2025-07-08 | participants survived more than five years from ALS symptom onset; the median survival in the group was 6.8 years Read More | FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BCLI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BCLI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How BCLI ranks across every disease it competes inCompetitive Position is a premium feature
See how BCLI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial